Skip to main content
. Author manuscript; available in PMC: 2011 Aug 20.
Published in final edited form as: Biochem Biophys Res Commun. 2010 Jul 21;399(2):245–250. doi: 10.1016/j.bbrc.2010.07.062

Figure 1.

Figure 1

Expression and activity of TCF7L2 isoforms in ECs. (A) Schematic representation of human TCF7L2 exon organization [3, 4], of TCF7L2 domains and of the major TCF7L2 forms expressed in HUVEC. The primer sets used to analyze the expression of total TCF7L2 mRNA (T) and the alternative exons-4/6 (Ex3–9) and exons-13/16 (Ex12–17) are represented. (B) RT-PCR analysis of the TCF7L2 mRNA isoforms expressed in ECs with different tissue origins and immortalization status. The PCR products were resolved on 1% agarose gels. (C) Analysis of the transcriptional β-catenin/TCF7L2 isoforms activity in BAEC using co-transfection of S37A-β-catenin with TCF7L2 variants as indicated and TOP/FOP-Flash reporter assays (Mean±SEM, n=4–5). A representative western-blot analysis of the endogenous and exogenous TCF7L2 isoforms is shown.